Evaluation of platelet-rich plasma from diabetic donors shows increased platelet vascular endothelial growth factor release

Karina, Komang Ardi Wahyuningsih, Siti Sobariah, Iis Rosliana, Imam Rosadi, Tias Widyastuti, Irsyah Afini, Septelia Inawati Wanandi, Pradana Soewondo, Heri Wibowo, Jeanne Adiwinata Pawitan

Research output: Contribution to journalArticlepeer-review

12 Citations (Scopus)


Background: Platelet-rich plasma (PRP) contains pro-angiogenic growth factors including vascular endothelial growth factor (VEGF). Angiogenesis is a necessary component of wound healing in instances of diabetic foot ulcers (DFU). PRP composition varies depending on methods and donor health status. Our group has developed an improved PRP protocol for diabetes treatment. The aims of this study were to examine the levels of the pro-angiogenic factor VEGF in these patient populations with and without diabetes. Methods: PRP was prepared using 24 mL of whole blood from 13 diabetic and 10 non-diabetic patients registered at Klinik Hayandra. Whole blood in sodium citrate tubes were centrifuged at 1,000 rpm for 5 minutes followed by plasma separation. Plasma samples were centrifuged at 3,000 rpm for 5 minutes. Upper platelet-poor plasma layers were discarded, leaving 5 mL of concentrated platelet containing plasma (PRP). Concentrated plasma samples were mixed, aliquoted, stored at −86 ℃, and pooled for platelet count, VEGF, and total protein analyses. Platelet counting was also performed using fresh whole blood and PRP to measure changes following PRP preparation. Results: Diabetic donors had higher whole blood platelet counts than non-diabetic donors, but this difference was not statistically significant. An average increase of more than 250% in platelet number after PRP preparation using our method was noted in both groups. Freezing-thawing samples at −86 ℃ lysed more than 90% of PRP platelets regardless of diabetes status. Diabetic PRP had lower mean total protein and higher VEGF concentrations. Lysed platelets from diabetic donors released more VEGF than those from non-diabetic donors. Conclusions: PRP from diabetic donors had higher VEGF content making autologous PRP application a promising treatment for DFU. However, this should be investigated another appropriate clinical trial.

Original languageEnglish
Article number43
JournalStem Cell Investigation
Publication statusPublished - 1 Dec 2019


  • Angiogenesis
  • Diabetes
  • Diabetic foot ulcer (DFU)
  • Platelet-rich plasma (PRP)
  • Vascular endothelial growth factor (VEGF)


Dive into the research topics of 'Evaluation of platelet-rich plasma from diabetic donors shows increased platelet vascular endothelial growth factor release'. Together they form a unique fingerprint.

Cite this